A Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The overarching goals of this study are to measure levels of circulating tumor DNA (ctDNA) in patients with early stage diffuse large B cell lymphoma (DLBCL), to assess the change in ctDNA during treatment in order to prospectively identify markers of treatment failure, and to use ctDNA as a future tool for response adapted therapy.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Chłoniak B-komórkowy rozpoznany po raz pierwszy, na wczesnym etapie, bez dużych mas guza
- •Wiek co najmniej 18 lat
- •Zmiana widoczna w badaniach obrazowych (PET/CT)
- •Możliwość pobrania próbki guza do badań
- •Serce pracuje prawidłowo (wydolność ponad 50%)
- •Prawidłowa funkcja nerek
- •Prawidłowa funkcja wątroby
- •Wystarczająca ilość zdrowych komórek krwi
✗ Disqualifies
- •Ciąża lub karmienie piersią
- •Guz większy niż 10 cm
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- October 13, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
University of Rochester
Rochester, United States
Trial contact
Robin Boerman
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 10/14/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.